BiologicsFinancial

Orthobiologics Market for Bone Repair & Regeneration, 2018-2024 – Dominated by Medtronic, MTF Biologics, NuVasive, and Orthofix


DUBLIN, April 15, 2020 /PRNewswire/ — The “Orthobiologics for Bone Repair and Regeneration” report has been added to ResearchAndMarkets.com offering.

Over the forecast period covered by this report, the market for orthobiologics for the repair and regeneration of bone is projected to increase at a CAGR of 3.2%, from approximately $2,358 million in 2018 to $2,844.2 million in 2024.

This report comprises three market segments; allografts and synthetic grafts, growth factors, and cellular bone matrices (CBMs). Of the three segments, allografts and synthetic grafts contributed the greatest proportion (59%) of revenue in 2018, followed by growth factors (26%), and CBMs (15%).

Key drivers of the market for orthobiologics for the repair and regeneration of bone include:

  • The ageing of the population and the global burden of musculoskeletal disease
  • Increases in spinal fusion and arthroplasty procedure volumes
  • The use of orthobiologics, such as growth factors, that demonstrate a reduction in revision surgery rates
  • Clinical outcomes that show superiority to autograft in regard to safety/efficacy

Factors that will constrain growth in the global market for orthobiologics for bone repair and regeneration include:

  • The high price of premium products such as growth factors and CBMs
  • Limited reimbursement for certain CBM products
  • A hesitance in certain countries to use human-based tissue for bone grafts
  • Highly competitive markets, particularly for allografts and synthetic grafts

Leading competitors in this market include Medtronic, MTF Biologics, NuVasive, and Orthofix.

This analysis includes a discussion of products, current/forecast markets, and competitors in the global markets for orthobiologics for the repair and regeneration of bone. Market forecasts and spinal fusion procedure volumes are provided for the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World for 2018-2024.

Key Topics Covered

Executive Summary
i. Global market for bone repair orthobiologics
a. Selected market drivers and limiters
b. Market leaders
ii. Methodology

  • Exhibit ES-1: Orthobiologics for bone repair and regeneration, global market forecast ($m), by product segment, 2018-24
  • Exhibit ES-2: Orthobiologics for bone repair and regeneration, share by country/region, 2018

1. Clinical Overview
1.1 Spinal fusion
1.2 Primary research
1.3 Osteoarthritis

  • Exhibit 1-1: Spinal fusion procedure volumes, by country/region, 2018-24
  • Exhibit 1-2: Surgeon survey, use of bone grafts for lumbar spinal fusions, by type of graft, US, 2019
  • Exhibit 1-3: Surgeon survey, use of bone grafts for lumbar spinal fusions, by type of graft, Germany, 2019
  • Exhibit 1-4: Global osteoarthritis prevalence (knee or hip) forecast, by region, 2018-24

2. Allografts and Bone Graft Substitutes Market
2.1 Bone graft materials
2.1.1 Bone autograft
2.1.2 Bone allografts and machined bone
2.1.3 Demineralized bone matrix
2.1.4 Synthetic grafts
2.2 Global market analysis
2.3 Global competitive analysis
2.4 Bibliography

  • Exhibit 2-1: General categories of bone grafts
  • Exhibit 2-2: Clinical applications for bone grafts
  • Exhibit 2-3: Clinical applications for allografts and synthetic grafts in orthopedic surgery
  • Exhibit 2-4: Selected structural bone allografts
  • Exhibit 2-5: Prices of selected allografts (chips, crushed, and cubed)
  • Exhibit 2-6: Selected demineralized bone matrix products
  • Exhibit 2-7: Prices of Medtronic’s Grafton DBM gel and putty
  • Exhibit 2-8: Selected synthetic bone grafts
  • Exhibit 2-9: Prices of Medtronic’s Mastergraft synthetic bone graft
  • Exhibit 2-10: Global bone allograft products market, share by country/region, 2018
  • Exhibit 2-11: Global bone allograft product sales by country/region, market forecast ($m), 2018-24
  • Exhibit 2-12: Bone allografts and synthetic bone graft substitutes market, share by tissue type, 2018
  • Exhibit 2-13: Global bone allografts market, share by supplier, 2018

3. Bone Growth Factor Grafts
3.1 Bone morphogenetic proteins
3.2 Other growth factors
3.3 Discontinued product
3.4 Emerging product
3.5 Market analysis
3.6 Competitive analysis
3.7 Bibliography

  • Exhibit 3-1: Prices of Infuse bone morphogenetic protein
  • Exhibit 3-2: Selected growth factor-based orthobiologic products
  • Exhibit 3-3: Growth factor bone graft sales, market forecast, by country/region ($m), 2018-24
  • Exhibit 3-4: Global growth factor bone grafts products market, share by country/region, 2018
  • Exhibit 3-5: Growth factor bone grafts, market forecast, by product line ($m), 2018-24
  • Exhibit 3-6: Global growth factor bone grafts market, share by supplier, 2018
  • Exhibit 3-7: Medtronic net sales ($m), by fiscal year and company division

4. Cellular Bone Matrices Market
4.1 Products
4.2 Market analysis
4.3 Competitive analysis
4.4 Bibliography

  • Exhibit 4-1: Selected cellular bone matrix products
  • Exhibit 4-2: Prices of selected cellular bone matrix products
  • Exhibit 4-3: Global cellular bone matrix product sales by country/region, combined market forecast ($m), 2018-24
  • Exhibit 4-4: Global cellular bone matrix products market, share by country/region, 2018
  • Exhibit 4-5: Global cellular bone matrix products market, share by supplier, 2018

Appendix: Company Listing

For more information about this report visit https://www.researchandmarkets.com/r/dbsd6y

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Print Friendly, PDF & Email
Tags

Mike Adams

Mike Adams is a medical device sales leader with extensive clinical experience in spine and biologics and a nationwide distribution network built over the last 10+ years in the industry. He has held various leadership positions in healthcare and device including Distributor Partner, Hospital COO and Spine VP of Sales. He currently leads the commercialization strategy for OrthoSpine Partners and is a Distributor Principal at Novel Medical. Because of his unique career path, Mike has the ability to see the healthcare business from multiple perspectives making him passionate about building strategic partnerships that help reduce overall costs, drive innovation, and cultivate growth for new markets.

Related Articles

Back to top button
Close